What is a stock summary page? Click here for an overview.
Business Description
HUTCHMED (China) Ltd
ISIN : US44842L1035
Share Class Description:
FRA:H7T1: ADRCompare
Compare
Traded in other countries / regions
HCM.UK00013.Hong KongHCM.USAH7T2.GermanyHCM.Mexico IPO Date
2016-03-30Description
HUTCHMED (China) Ltd is an biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 9.31 | |||||
| Equity-to-Asset | 0.6 | |||||
| Debt-to-Equity | 0.12 | |||||
| Debt-to-EBITDA | 6.31 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | 3.46 | |||||
| Beneish M-Score | -1.89 | |||||
| WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 19.1 | |||||
| 3-Year FCF Growth Rate | 57.6 | |||||
| 3-Year Book Growth Rate | -6.8 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 25.12 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 49.87 | |||||
| 9-Day RSI | 50.07 | |||||
| 14-Day RSI | 50.92 | |||||
| 3-1 Month Momentum % | 6.47 | |||||
| 12-1 Month Momentum % | -6.92 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.83 | |||||
| Quick Ratio | 2.7 | |||||
| Cash Ratio | 2.22 | |||||
| Days Inventory | 51.34 | |||||
| Days Sales Outstanding | 82.92 | |||||
| Days Payable | 42.66 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | 0.1 | |||||
| Shareholder Yield % | 0.47 |
Profitability Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 44.65 | |||||
| Operating Margin % | -6.44 | |||||
| Net Margin % | 5.98 | |||||
| FCF Margin % | -2.59 | |||||
| ROE % | 5.07 | |||||
| ROA % | 2.96 | |||||
| ROIC % | -59.11 | |||||
| 3-Year ROIIC % | 17.01 | |||||
| ROC (Joel Greenblatt) % | 1.97 | |||||
| ROCE % | 0.22 | |||||
| Years of Profitability over Past 10-Year | 4 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 73.99 | |||||
| Forward PE Ratio | 137.5 | |||||
| PE Ratio without NRI | 73.99 | |||||
| PS Ratio | 4.16 | |||||
| PB Ratio | 3.37 | |||||
| Price-to-Tangible-Book | 3.24 | |||||
| Price-to-Operating-Cash-Flow | 2367.55 | |||||
| EV-to-EBIT | 938.86 | |||||
| EV-to-Forward-EBIT | -37.83 | |||||
| EV-to-EBITDA | 127.76 | |||||
| EV-to-Forward-EBITDA | -38.6 | |||||
| EV-to-Revenue | 2.89 | |||||
| EV-to-Forward-Revenue | 2.48 | |||||
| EV-to-FCF | -116.14 | |||||
| Price-to-GF-Value | 0.8 | |||||
| Price-to-Median-PS-Value | 0.31 | |||||
| Price-to-Graham-Number | 3.2 | |||||
| Price-to-Net-Current-Asset-Value | 4.45 | |||||
| Price-to-Net-Cash | 7.57 | |||||
| Earnings Yield (Greenblatt) % | 0.11 | |||||
| FCF Yield % | -0.67 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
HUTCHMED (China) Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 593.895 | ||
| EPS (TTM) (€) | 0.187 | ||
| Beta | 1.26 | ||
| 3-Year Sharpe Ratio | 0.09 | ||
| 3-Year Sortino Ratio | 0.14 | ||
| Volatility % | 33.1 | ||
| 14-Day RSI | 50.92 | ||
| 14-Day ATR (€) | 0.419862 | ||
| 20-Day SMA (€) | 14.63 | ||
| 12-1 Month Momentum % | -6.92 | ||
| 52-Week Range (€) | 12.3 - 19.9 | ||
| Shares Outstanding (Mil) | 170.98 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
HUTCHMED (China) Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
HUTCHMED (China) Ltd Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| No Event Data | ||||
HUTCHMED (China) Ltd Frequently Asked Questions
What is HUTCHMED (China) Ltd(FRA:H7T1)'s stock price today?
The current price of FRA:H7T1 is €14.30. The 52 week high of FRA:H7T1 is €19.90 and 52 week low is €12.30.
When is next earnings date of HUTCHMED (China) Ltd(FRA:H7T1)?
The next earnings date of HUTCHMED (China) Ltd(FRA:H7T1) is 2025-07-31 Est..
Does HUTCHMED (China) Ltd(FRA:H7T1) pay dividends? If so, how much?
HUTCHMED (China) Ltd(FRA:H7T1) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers